Guideline on treatment intensification with injectable therapies…
Clear evidence guides doctors to switch to newer dual-action diabetes drugs when single GLP-1 therapy isn't enough, offering better blood sugar and weight control.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
The requirement of MALT1 activity for the growth of adult T cell…
A new drug targeting MALT1 shows promise in lab and animal models of aggressive T-cell leukemia, particularly for patients whose tumors have specific genetic markers.
Promising but preliminarySepsis risk in patients with COPD and type 2 diabetes mellitus
GLP-1 drugs substantially reduce sepsis and death risk in patients struggling with both COPD and type 2 diabetes, compared to another common medication.
Promising but preliminaryGSK3B variations influence renoprotective responses to dapagliflozin…
A genetic test may help predict which diabetic kidney disease patients will benefit most from dapagliflozin, moving toward personalized treatment decisions.
Promising but preliminaryJMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating…
A new immunotherapy designed to avoid the dangerous side effects of older IL-2 drugs shows strong tumor control in early models without systemic toxicity.